Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
Comparing overall survival in patients with metastatic prostate cancer using PSA levels: A multivariate analysis using a national database. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Fear of recurrence among uninsured and underrepresented prostate cancer survivors of the Men's Health Study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results